Skip to main content
. 2023 Nov 23;11(12):3124. doi: 10.3390/biomedicines11123124

Figure 6.

Figure 6

Diseases targeted in ocular gene augmentation trials (top) and their distribution by start year (bottom). The separated piece of pie indicates acquired conditions (top).